These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 32092958)

  • 1. Current Advances in the Treatment of BRAF-Mutant Melanoma.
    Patel H; Yacoub N; Mishra R; White A; Long Y; Alanazi S; Garrett JT
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32092958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.
    Trojaniello C; Festino L; Vanella V; Ascierto PA
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):259-266. PubMed ID: 30652516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings.
    Broman KK; Dossett LA; Sun J; Eroglu Z; Zager JS
    Expert Opin Drug Saf; 2019 May; 18(5):381-392. PubMed ID: 30977681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
    Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Strudel M; Ascierto PA
    Am J Clin Dermatol; 2017 Dec; 18(6):745-754. PubMed ID: 28537004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma.
    Kakadia S; Yarlagadda N; Awad R; Kundranda M; Niu J; Naraev B; Mina L; Dragovich T; Gimbel M; Mahmoud F
    Onco Targets Ther; 2018; 11():7095-7107. PubMed ID: 30410366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.
    Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA
    BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
    Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achievements and challenges of molecular targeted therapy in melanoma.
    Sullivan R; LoRusso P; Boerner S; Dummer R
    Am Soc Clin Oncol Educ Book; 2015; ():177-86. PubMed ID: 25993155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for
    Hamid O; Cowey CL; Offner M; Faries M; Carvajal RD
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31653096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
    Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
    Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma.
    Schulz A; Raetz J; Karitzky PC; Dinter L; Tietze JK; Kolbe I; Käubler T; Renner B; Beissert S; Meier F; Westphal D
    Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF and MEK inhibition in melanoma.
    Dossett LA; Kudchadkar RR; Zager JS
    Expert Opin Drug Saf; 2015 Apr; 14(4):559-70. PubMed ID: 25648338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
    Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C
    Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
    Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.
    Graf NP; Koelblinger P; Galliker N; Conrad S; Barysch M; Mangana J; Dummer R; Cheng PF; Goldinger SM
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):686-692. PubMed ID: 30468696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.